MARY LEE: Open Payments
NPI 1194277244 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,457 in 28 payments from 9 companies in 2025. Trend: 2023 $2,556 · 2024 $2,616 · 2025 $1,457
Consulting: $740Food & beverage: $717
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 4 | $876 |
| Alkermes, Inc. | 6 | $239 |
| Teva Pharmaceuticals USA, Inc. | 4 | $93 |
| Lundbeck LLC | 5 | $81 |
| Neurocrine BioSciences, Inc. | 3 | $59 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Otsuka America Pharmaceutical, Inc. | 2 | $32 |
| Abbott Laboratories | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $15 |
Products named: COBENFY, LYBALVI, ARISTADA, REXULTI, INGREZZA, UZEDY, ABILIFY ASIMTUFII, AUSTEDO XR.
Industry payments across AL — which companies pay providers there.
